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Abstract
Mutations in the dysferlin gene are the cause of Limb-girdle Muscular Dystrophy type 2B and Miyoshi Myopathy. The
dysferlin protein has been implicated in sarcolemmal resealing, leading to the idea that the pathophysiology of dysferlin
deficiencies is due to a deficit in membrane repair. Here, we show using two different approaches that fullfiling membrane
repair as asseyed by laser wounding assay is not sufficient for alleviating the dysferlin deficient pathology. First, we
generated a transgenic mouse overexpressing myoferlin to test the hypothesis that myoferlin, which is homologous to
dysferlin, can compensate for the absence of dysferlin. The myoferlin overexpressors show no skeletal muscle abnormalities,
and crossing them with a dysferlin-deficient model rescues the membrane fusion defect present in dysferlin-deficient mice
in vitro. However, myoferlin overexpression does not correct muscle histology in vivo. Second, we report that AAV-mediated
transfer of a minidysferlin, previously shown to correct the membrane repair deficit in vitro, also fails to improve muscle
histology. Furthermore, neither myoferlin nor the minidysferlin prevented myofiber degeneration following eccentric
exercise. Our data suggest that the pathogenicity of dysferlin deficiency is not solely related to impairment in sarcolemmal
repair and highlight the care needed in selecting assays to assess potential therapies for dysferlinopathies.
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Introduction
Mutations in dysferlin have been shown to lead to a variety of
muscle phenotypes that range from mild to severe, including the
prominent Limb-Girdle Muscular Dystrophy type 2B [LGMD2B;
OMIM 253601; [1]] and Miyoshi Myopathy (MM, OMIM
254130, [2]]. These muscular dystrophies (MD) are characterized
by progressive muscle atrophy and weakness arising in the late
teens but differ in the pattern of muscle involvement: proximal in
LGMD2B and distal in MM. Electron microscopy analysis of
muscle biopsies from LGMD2B or MM patients reveals numerous
structural membrane defects such as disruption of the plasma
membrane, alterations in the basal lamina and subsarcolemmal
accumulation of vesicles [3]. Both naturally occurring and
genetically engineered murine models of dysferlin deficiency also
show dystrophic changes and loss of membrane integrity [4,5,6].
Dysferlin deficiency in these models has been associated with
defective membrane resealing of isolated skeletal muscle fibers,
a calcium-dependent process involving recruitment of internal
vesicles at the site of membrane damage and fusion with the
plasma membrane [7]. Changes in the immune system, including
increased phagocytic activity in dysferlin-deficient macrophages
and enhanced susceptibility to complement attack, have also been
proposed to exacerbate the pathophysiology of the disease
[8,9,10]. However, restoring dysferlin in muscle alone is sufficient
to mitigate the dystrophic phenotype [11] suggesting that the
primary defect due to the absence of dysferlin lies within the
muscle fibers themselves, and not in cells of the immune system.
Dysferlin is a ,230 kDa membrane-anchored protein in the
ferlin family that is composed of a C-terminal transmembrane
domain and a very long N-terminal cytoplasmic domain with up
to 7 predicted C2 domains (C2A to C2G) that are classically
involved in the calcium dependent binding to phospholipids and
proteins [12,13]. Dysferlin is expressed strongly in skeletal muscle,
heart, placenta and monocytes [1,2,14]. Myoferlin, the ferlin with
the greatest sequence homology to dysferlin (56%), is expressed in
placenta, heart, lung, endothelial cells but also, at lower levels, in
cardiac and skeletal muscles [15]. In these latter tissues, the two
ferlin proteins are associated with plasma and T-tubule mem-
branes, with an additional association with nuclear membrane for
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myoferlin [15,16,17,18]. Although mutations in myoferlin have
not been associated to date with a human disease, elimination of
myoferlin in mice by homologous recombination leads to
a dystrophic phenotype with smaller myofibers and a reduced
capacity to regenerate after injury [19]. In addition to previously
reported role of dysferlin in membrane repair [6] and of myoferlin
in myoblast fusion [19], recent data support a role of these two
ferlins in intracellular vesicle trafficking [20].
No treatment is available for dysferlinopathies and gene therapy
is complicated by the fact that the dysferlin cDNA is large.
However, a strategy based on the capacity of the genomes of
different adeno-associated viruses (AAV) to concatemerize after
transduction restored the ability of the sarcolemma to repair in in
vitro assays and improved muscle function in vivo [21]. Identifica-
tion of mutations in dysferlin associated with mild phenotypes led
to the suggestion that exon skipping [22,23] or use of a small
version of dysferlin that would have retained most of the protein’s
activity – ‘‘a minidysferlin’’ [24] - hold promise for the
development of new therapeutic strategies.
In this report, we used transgenic mice to learn if over-
expression of myoferlin can compensate for dysferlin deficiency.
We observed that myoferlin overexpression can compensate for
the membrane fusion defect seen in laser wounding assays of
dysferlin-null muscle fibers in vitro but it did not improve muscle
histology in vivo. Similarly, a form of minidysferlin, cloned from
a patient with a mild clinical presentation, expressed in muscle via
an AAV vector, although previously shown to be efficient in
rescuing sarcolemmal repair in vitro, did not prevent the de-
velopment of a dystrophic phenotype in mice. Furthermore,
neither of the two therapeutic approaches prevented irreversible
damage to muscle following eccentric exercise in vivo. Conse-
quently, the in vitro impairment of sarcolemmal resealing associated
with dysferlin deficiency is likely a by-stander effect that is not
directly linked to the pathogenicity.
Results
Design and Characterization of the Myoferlin Transgenic
Mice
To test the hypothesis that myoferlin, the closest member of the
ferlin family to dysferlin, could compensate for dysferlin deficiency,
we developed a transgenic mouse carrying the murine myoferlin
cDNA under the transcriptional control of the chicken b-actin
(CAG) promoter at the hypoxanthine-guanine phosphoribosyl
transferase (hprt) locus (Figure 1A).
The resulting model, which we refer to as TgMyof, produces
litters of normal size, sex ratio and longevity. We analyzed
myoferlin mRNA expression by quantitative RT-PCR (qRT-PCR)
in 6-month-old male animals to determine the extent of over-
expression of myoferlin (Figure 1B). In the three muscles examined
[Psoas (Pso), Quadriceps (Qua) and Tibialis Anterior (TA)], the mRNA
encoding myoferlin was overexpressed in the transgenic line more
than 200-fold compared to C57BL/6. When quantified on serial
dilutions of the myoferlin plasmids, the mean copies number in the
WT and TgMyof was defined as 46107 (63.96106) and 1061010
(66.76108) copies per mg RNA. We then analyzed protein
expression by western blotting with a myoferlin antibody using TA
muscles from mice at two different ages (3 weeks and 4 months).
We observed that myoferlin is more expressed in young WT mice
and is barely visible in older mice (Figure 1C). Quantification
indicated that myoferlin protein levels were 4 and 100 times higher
in muscles of the transgenic mouse at 3 weeks and 4 months of age,
respectively, compared to WT (p,0.05). Immunostaining experi-
ments performed on PSO sections showed that myoferlin was
concentrated in the sarcolemmal region of the fibers (Figure 1D,
middle panel). This localization was not different from what was
observed in the wild-type animals (Figure 1D, left panel). In
subcellular fractionation experiments, myoferlin was found in the
same sub-cellular compartments (cytosol, membrane and nuclear
fractions) in TgMyof and WT muscles (Figure S1A). No significant
difference in skeletal muscle weight was observed between TgMyof
and C57BL/6 (Figure 1E). No histopathological abnormal
features, including centrally nucleated fibers (CNF) could be
observed in the skeletal muscle of these mice in Hematoxylin-
Phloxine-Saffron (HPS) stained sections from 9-month-old animals
(Figure 1F). The contractile function of TgMyof muscles was
compared with WT muscles at 2 months of age using a tetanic
stimulation for 300 ms (n = 4). The maximal tetanic torques
generated by the anterior compartment of the leg of TgMyof and
WT (2.860.6 and 2.360.5 N.mm, respectively) or the ratios of
torque to the weight of the muscles (59610 and 43610 N.mm/g,
respectively) were not statistically different (Figure S1B).
Myoferlin Overexpression Restores Sarcolemmal Repair in
Dysferlin-deficient Muscle
To determine whether increased myoferlin levels could amelio-
rate the phenotype resulting from dysferlin deficiency, the
transgenic mice were crossed with dysferlin-deficient mice
[B6.A/J-Dysf prmd] to generate TgMyof/Dysf prmd. We verified by
western blot analysis that myoferlin was still overexpressed
(Figure 2A). We analyzed the sarcolemmal repair capacity in
isolated Flexor Digitorum Brevis (FDB) fibers of 1-month-old animals
by performing laser-wounding in the presence of FM1-43 dye, as
previously described [6,25]. In this assay, isolated muscle fibers
from WT mice successfully repair membrane lesion in the
presence of calcium, as seen by the rapid halt of dye entry,
whereas Dysf prmd fibers do not (Figure 2B). Remarkably, fibers
from TgMyof as well as from TgMyof/Dysf prmd responded to laser
wounding like wild-type mice, by showing rapid stabilization of
intracellular fluorescence due to FM1-43 (Figure 2B). This result
indicates that expression of myoferlin in the absence of dysferlin
was able to promote sarcolemmal repair after laser wounding.
Improvement of Membrane Repair Capacity does not
Result in Reduction of Dystrophic Changes in Dysferlin-
deficient Muscle
To analyze whether the restoration of membrane repair
capacity was associated with improvement of muscle health, we
investigated the impact of myoferlin overexpression at the
histological level in dysferlin-deficient muscles. Qua and TA
muscles from TgMyof and TgMyof/Dysf prmd were sampled in 6-
month-old animals. Examination of HPS-stained sections showed
that the histology of the muscle was not improved with the
overexpression of myoferlin, despite their improved response to
laser wounding, since they showed a high level of dystrophic
features (Figure 2C). In particular, CNF were at similar levels to
those of age-matched Dysf prmd mice (Figure2D). These results
suggest that overexpression of myoferlin is not sufficient to correct
the dystrophic phenotype associated with dysferlin deficiency.
We next examined if a naturally occurring deletion variant of
dysferlin (Figure S2A) could restore dysferlin-null muscles to
health. This minidysferlin was originally identified in a patient
with a mild form of dysferlinopathy with little dystrophic features,
in particular with a very low level of CNF and shown to restore the
membrane repair capacity of dysferlin-null muscle, following laser
wounding [24]. Four-week-old Dysf prmd male mice were injected in
the left TA with rAAV2/1 vectors [1.26109 viral genome (vg)]
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Figure 1. Characterization of the Myoferlin transgenic mice. A/Schematic representation of the Myof construct and Hprt targeted allele. B/
Quantitative RT-PCR for myoferlin expression in muscles of WT and TgMyof revealed a 200-fold greater expression in the transgenic. The data are
presented relative to a titration with the original myoferlin expression plasmid. (** p,0.01 between WT and TgMyof). C/Western blot for the
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myoferlin protein in WT and TgMyof showing the overexpression in the transgenic animals (results for 2 animals at 3 weeks and 4 months of age are
shown). A-actinin staining was used to confirm that similar amounts of total protein extracted from muscles were loaded for all samples. D/
Immunofluorescence of myoferlin in sections of WT (left panel) and TgMyof (middle panel) muscles. A control in which the primary antibody was
omitted is shown (right panel). Scale bar = 50 mm. E/Weight of WT and TgMyof muscles at 9 months of age. The values of TgMyof muscles are not
statistically significant compared with WT mice (p.0.05). F/Histological analysis of 9-month-old male TgMyof showed no abnormality. Scale
Bar = 50 mm.
doi:10.1371/journal.pone.0038036.g001
Figure 2. Myoferlin overexpression improves sarcolemmal repair after laser wounding but do not improve muscle histology. A/
Western blot for the myoferlin protein in Dysf prmd and TgMyof/Dysf prmd FDB muscles shows the overexpression of myoferlin in TgMyof/Dysf prmd
(results for 2 animals are shown for each muscle and condition). A-Actin was used as loading control. B/Box plots represent the rate of change of
fluorescence (D[fluorescence]/Dt) in the fibers of WT (n = 29), Dysf prmd (n = 14), TgMyof (n = 31) and TgMyof/Dysf prmd (n = 17). Boxes extend from the
25th to the 75th percentile values. Minimum and maximum values are indicated by the dots at the end of the vertical lines. Horizontal bold bars
indicate the median value. **p,0.01 compared to dysferlin-deficient mice. Results indicate that overexpression of myoferlin restores membrane
repair in the absence of dysferlin. C/Histological analysis of Qua and TA of 6-month-old Dysf prmd and TgMyof/Dysf prmd. Necrotic fibers, CNF, cellular
infiltrations and fiber size variations are seen in Dysf prmd and TgMyof/Dysf prmd muscle. Scale bar = 50 mm. D/CNF were counted in HPS-stained
transverse cryosections from WT, TgMyof, Dysf prmd and TgMyof/Dysf prmd 6-month-old mice. The number of CNF in TgMyof/Dysf prmd are not
significantly different when compared with Dysf prmd mice.
doi:10.1371/journal.pone.0038036.g002
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carrying the minidysferlin under the control of the C5-12
promoter. The TA muscles were sampled 7 weeks after injection.
RT-qPCR performed with primers at the end of the dysferlin
cDNA showed that 20-fold more minidysferlin is expressed
compared to amount of full-length dysferlin in a normal human
skeletal muscle (data not shown). Immunoblot analyses were also
performed on extracts of these muscles and confirmed the
upregulation of the minidysferlin compared to endogenous
dysferlin (Figure S2B). Similarly to what we found with over-
expression of myoferlin, the histology of the transduced muscles
was not improved since HPS-stained sections showed a high level
of dystrophic features, including many fibers with centrally located
nuclei (Figures 3A and B). A possible toxic effect of minidysferlin
overexpression can even be noted since the level of centronuclea-
tion is significantly higher in the injected Dysf prmd than in the
noninjected muscles (p,0.05).
To ascertain this possible toxic effect, we injected different doses
(from 9.36107 to 1.661010 vg) of AAV-minidysferlin in TA of WT
animals and sampled the muscles 4 weeks later. We used two
different viral preparations to circumvent any possible effect due to
the quality of the preparation. The level of expression of
minidysferlin was quantified by qRT-PCR and ranged from
0.06 to 21 fold compared to dysferlin expression in a healthy
human muscle control. Morphometrical analysis of HPS-stained
muscle sections showed that the muscles injected with the lowest
doses were completely normal and that the muscles injected with
doses that lead to an expression of minidysferlin higher than
a corresponding level of dysferlin in normal muscle exhibit
a number of CNF that increase with the dose (Figure 3C). We
performed a similar experiment with Dysf prmd mice and found that
an expression of minidysferlin equivalent to the level of dysferlin in
normal muscle did not lead to a modification of the number of
CNF in Dysf prmd muscle (Figure 3D). This observation suggests
that even a non toxic dose of minidysferlin is not able to reverse
the dysferlin related pathology. In contrast, an excess of
minidysferlin as low as 6-fold led to an important increase in
CNF (Figure 3D). Immunofluorescence detection of the protein
was performed in sections of WT and Dysf prmd muscles non
injected and injected with high doses of AAV-minidysferlin. Spots
of intense fluorescence were seen throughout the cytoplasm in
injected conditions, suggesting accumulation/aggregation of the
minidysferlin protein (Figure 3E).
AAV-mediated Transfer of Minidysferlin and Myoferlin
Overexpression do not Prevent Myofiber Degeneration
Following Eccentric Contractions in Dysferlin-deficient
Muscle
We studied muscles from animals subjected to our experimental
therapeutic strategies for their ability to recover from eccentric
exercise using the Large Strain Injury (LSI) model [11,26,27]. LSI
produces an injury from which normal muscle recovers via local
repair without myogenesis. However, the recovery of dysferlin-null
muscle is characterized by widespread necrosis and inflammation,
which is subsequently followed by myogenesis [26,27]. In
particular, dysferlin-deficient muscle recovers after LSI more
slowly than WT and shows much higher level of necrosis 3 days
after injury [26]. Four-week-old WT and Dysf prmd male mice were
injected in the left TA with 1.26109 vg of rAAV2/1-minidysferlin.
As a positive control for recovery, a group of Dysf prmd mice were
injected in the left TA with the dual AAV vectors encoding full-
length dysferlin (46109 vg each vector) that promote sarcolemmal
repair and correction of muscle pathology [21]. Six weeks after
injection, these two groups of mice, together with WT, TgMyof
and TgMyof/Dysf prmd mice, were subjected to the LSI protocol
and allowed to recover for 3 days. Evans Blue Dye (EBD) was
injected intraperitoneally one day before sacrifice to follow the
post injury necrosis that was previously observed to occur in
dysferlin-deficient muscles 3 days after LSI [26]. Left and right
(uninjected) TA muscles were sampled and effective transfer of
rAAV2/1-minidysferlin was validated by western blot (data not
shown). Examination of cryosections by fluorescence microscopy
revealed no EBD uptake in WT, full length dysferlin or TgMyof
muscles (Figures 4A and B). In contrast, minidysferlin-injected and
TgMyof/Dysf prmd myofibers demonstrated pronounced EBD
uptake at levels which were statistically indistinguishable from
the Dysf prmd mice (p.0.05) although the presence of high level of
myoferlin seems to have a slight positive effect. Accordingly, the
fiber necrosis that is present in dysferlin-deficient muscle 3 days
after an in vivo injury does not appear to be corrected by over-
expression of myoferlin or minidysferlin–yet both facilitate re-
covery of myofibers subjected to laser wounding in vitro.
Discussion
We investigated the potency of two different strategies for
reversing the myopathology of dysferlin deficiency: overexpression
of myoferlin and AAV-mediated transfer of a minidysferlin. We
used a laser wounding assay of myofibers in tissue culture to assess
the efficacy of these treatments in promoting sarcolemmal repair,
histology to examine the dystrophic phenotype in vivo, and large
strain injury to assess the susceptibility of skeletal muscles to
damage from eccentric contractions. The results show that the
restoration of sarcolemmal repair afforded by each of these
therapeutic strategies is not associated with improvement of the
histology or full protection against myofiber degeneration
observed 3 days after injury from eccentric contractions. These
data indicate that dysferlin’s role in skeletal muscle in vivo is not
effectively assayed by laser wounding of myofibers in vitro, and that
the evaluation of therapeutic strategies based on that in vitro assay
should be re-examined.
The skeletal muscles of TgMyof mice overexpress 30-fold more
myoferlin than in WT, but are indistinguishable from WT muscles
in weight and morphology. Centrally located nuclei, tissue fibrosis
and necrosis, typical features of dystrophy, were not observed,
even in 9-month-old animals. Interestingly, several lines over-
expressing different levels of dysferlin, generated previously
[11,28], can show myopathology, depending on protein dosage.
One line with three-fold overexpression was phenotypically
indistinguishable from WT with no obvious tissue pathology or
no change in weight [11]. In another study, in which 3 lines of
mice overexpressing low (2-fold), medium (36-fold) and high (176-
fold) levels of dysferlin were examined [28], the low level was well
tolerated, but medium and high levels were not. The mice
expressing these elevated levels of dysferlin were kyphotic with an
irregular gait and a non-necrotic progressive muscular dystrophy
characterized by marked atrophy and weakness. From molecular
analysis of several proteins, the authors proposed that dysferlin
overexpression may alter the stoichiometric assembly of the
membrane repair complex or lead to deregulated intrasarcoplas-
mic Ca2+ homeostasis through generation of the Unfolded Protein
Response (UPR) which overwhelms the Endoplasmic Reticulum
Associated Degradation (ERAD) machinery [28].
The level of myoferlin overexpression in our transgenic mouse
was similar to the medium level of expression of dysferlin of Glover
et al. [28]. However, this level of overexpression does not lead to
morphological abnormality in the case of myoferlin, suggesting
that, unlike dysferlin, significant levels of overexpression of
Dysferlin Is More than Membrane Repair
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myoferlin in wild-type animals are not cytotoxic. One possibility is
that expressing myoferlin as a murine protein in mice, as we did,
would be less toxic than expressing a human version of dysferlin,
as by Glover et al, that, in a murine context, would have been more
difficult to fold, generating an ER stress response. Of course, even
higher levels of myoferlin expression than we have been able to
achieve may be cytotoxic. In contrast to overexpression of
myoferlin but in accordance with the dysferlin overexpression
studies, overexpression of minidysferlin seems also to have a toxic
effect starting with level of expression 6 times higher than the level
of dysferlin in normal muscle. Since a non toxic dose of
minidysferlin was not able to reduce the level of CNF in Dysf prmd
mice, it can be suggested than no compensation of the dysferlin
pathology was brought with the minidysferlin. However, the
patient from whom the minidysferlin was derivated shows
a moderately severe clinical presentation with a mild dystrophic
aspect on the biopsy. Therefore, it seems that a low level of this
protein prevents most of the pathological aspects if present from
the beginning, This fact also underlines that dysferlin-related
membrane fusion events may play an important role during
muscle development [18], while dysferlin function in mature
muscle would implicate additional pathways.
Our data indicates that myoferlin is competent in repairing
membrane tears, even if only partially present at the sarcolemma.
Interestingly, this competency may participate in the fact the
dysferlin deficient myoblasts exhibit membrane repair as reported
[29].since myoferlin is highly expressed in myoblast [19].
Nevertheless, the inability of myoferlin to compensate for dysferlin
deficiency despite their similar structure and presumptive
fusogenic functions indicates that dysferlin performs functions
vital to muscle homeostasis that myoferlin cannot perform. Indeed,
the need for two highly homologous proteins in the same tissue
argues in favor of unique function with spacio-temporal specify for
each of these proteins. Their expression profiles together with
experimental data suggest a role for myoferlin in myoblast fusion
and for dysferlin in postfusion myotubes and myofibers while both
seem implicated in receptor recycling [15,17,19,30,31,32,33].
Further study is needed to ascertain the crucial functions that
dysferlin performs that are relevant to the onset and progression of
dysferlinopathies.
The differences in function between dysferlin and myoferlin
may be due to differences in the proteins with which they interact,
preventing a function to be fulfilled or else trapping the proteins in
different compartment. Similarly, the inability of minidysferlin to
compensate for dysferlin deficiency may also be due to its inability
to interact with the same proteins or regulate the same processes as
the full-length protein. Several binding partners of dysferlin have
been reported to date [34,35,36,37,38,39,40]. However, for all but
AHNAK, the relative corresponding interaction with myoferlin is
not known. Among dysferlin’s partners, AHNAK and tubulin are
known to interact with the N-terminus part of dysferlin. Therefore,
their binding sites are likely to be missing in the minidysferlin.
These proteins would be the first to be further looked at to define
whether the loss of the corresponding interaction would partici-
pate in the pathogenesis of dysferlinopathies. On this basis, we are
currently developing mididysferlins by adding additional domains
to the minidysferlin to promote protein interactions, while
maintaining a final size of the corresponding cDNA in the
packaging range of rAAV vectors for efficient muscle gene
transfer.
Our results indicate that restoration of sarcolemmal repair after
laser wounding in vitro does not correlate with a decrease in
dystrophic changes seen in dysferlin-deficient mice. Therefore, the
laser wounding assay does not seem sufficient for determining the
functionality of dysferlin in muscle, as it does not report the actual
dystrophic state of muscle accurately. This raises questions about
the validity of the assay, and whether it is appropriate for studying
dysferlin’s function in muscle fibers in vitro. It also suggests the need
for a different in vitro assay that produces results consistent with in
vivo criteria of human pathology. A deeper understanding of the
function of dysferlin with respect to vesicle trafficking or
inflammation, for example, may be required for this purpose.
In conclusion, our data demonstrate that myoferlin and
a minidysferlin can compensate for dysferlin-deficiency in an in
vitro assay of sarcolemmal repair but not for the defects in muscle in
vivo that lead to muscular dystrophy associated with the absence of
dysferlin. These observations suggest that, either correction of
sarcolemmal repair is not sufficient to prevent pathology or that
the laser wounding method, which we and others have used, does
not accurately assess the biological activity of dysferlin. Our results
highlight the care needed in selecting assays to assess potential
therapies for dysferlinopathies.
Materials and Methods
In vivo Experiments
All procedures on animals were performed in accordance with
the directive of 24 November 1986 (86/609/EEC) of the Council
of the European Communities and were approved by Genethon’s
ethics committee under the number CE11_013 and CE11_014.
C57BL/6 mice were purchased from Charles River Laboratories
(Les Oncins, France). [Tg(myof)1Iri] mice also called TgMyof
were generated by Speedy MouseH Technology (Nucleis, France)
to produce a single-copy transgene insertion at the hprt locus. The
coding sequence of murine myoferlin was cloned into the
polylinker of the GatewayH pENTR-1A vector (Invitrogen)
previously modified to include the ubiquitous chicken b-actin
(CAG) hybrid promoter. The transgene was then transferred by
Gateway technology into a destination vector pDEST-HPRT
(Nucleis) carrying two homologous arms of the hprt gene. The
Figure 3. Minidysferlin do not improve muscle histology. A/Histological analysis of Qua and TA of injected and non-injected 2-3-month-old
Dysf prmd mice by HPS staining. Necrotic fibers, CNF, cellular infiltrations and fiber size variations are seen in both injected and non-injected Dysf prmd
mice. Scale Bar = 100 mm. B/CNF were counted in HPS-stained transverse cryosections from injected and non-injected Dysf prmd mice and normalized
to the surface area of the muscle. No reduction in number of CNF in Dysf prmd mice after AAV-mediated transfer of minidysferlin was observed
(p.0.05). C/Level of CNF in TA muscles of WT animals injected with different doses of two different preparations (prep.1 and prep.2) of AAV-
minidysferlin. The level of minidysferlin expression was quantified by qRT-PCR and compared to the level of endogeneous dysferlin in a normal
human muscle. The ratio is indicated below the graph. The results are ordered according to the dysferlin expression level that was obtained. D/
Quantification of CNF in muscles of Dysf prmd mice that expressed an equivalent level of minidysferlin than dysferlin in normal muscle and 6 times this
dose. No decrease in the number of CNF was seen with the dose giving a level of minidysferlin equivalent to the dysferlin expression (x = 1) whereas
an important increase in seen with the dose leading to a 6-fold increase of expression (x = 6). It should be noted that this fold correspond to a mean
expression and that each individual fiber can express more or less than this means. E/Immunofluorescence of dysferlin in sections of muscles in the
Dysf prmd and WT mice. The non injected muscles are on the left of the figure and the muscles injected with AAV-minidysferlin on the right. Spots of
intense fluorescence were seen throughout the cytoplasm in injected conditions, suggesting accumulation/aggregation of the minidysferlin protein.
Scale bar = 50 mm.
doi:10.1371/journal.pone.0038036.g003
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vector was linearized using PvuI and electroporated into hprt
deficient BPES-embryonic stem (ES) cells by standard methods.
The targeting construct contained the missing sequences in BPES
ES cells and two regions of homology of the hprt gene that allowed
insertion of the transgene at this locus (Figure 1). The targeted ES
clones were efficiently selected, due to the restoration of the ability
to grow in Hypoxanthine-Aminopterin-Thymidine (HAT) medi-
um as a result of correct homologous recombination.
Genotyping of HAT-resistant ES clones was performed by PCR
analysis of genomic DNA with the following primers: GenetBS2.s
59-TGCAAGACCATGCGCTTCAT-39, HPRT.as 59- GA-
TAGGTCAGGTAAGCAAGCAAC -39 and HPRTm-int1a 59-
CCCCTTCCCTTTTCTCCCTC -39 and HPRTm-int1as 59-
CTAAGGCAGGAGGATTCCAG -39. Using these primers, the
wild-type locus gives a band of 300 bp and the mutant form,
a band of 1900 bp. Samples were amplified for 30 cycles, each
consisting of denaturation at 94uC for 40 s, annealing at 60uC for
40 s, and elongation at 72uC for 40 s. Targeted ES cells were
injected into C57BL/6-derived blastocysts that were then
transplanted into the uteri of recipient females. Resulting chimeric
males were bred with C57BL/6 females, and the N1 agouti female
offspring were backcrossed with C57BL/6 males. The resulting
heterozygous mice were crossed together; homozygous females
resulting from this cross were crossed with hemizygous males to
generate the line.
TgMyof/Dysf prmd were generated through successive back-
crossing of TgMyof males with Dysf prmd females. Dysferlin
genotyping was performed on tail DNA as described [5].
Hemizygous TgMyof females were crossed with Dysf prmd males
[25]. Genotyping of the progeny was performed to identify the
mice that were homozygous for the Dysf prmd mutation while
carrying myoferlin transgene.
C57Bl/6 mice were purchased from Charles River Laboratories
(Les Oncins, France). Dysf prmd mice backcrossed onto C57BL/6
background through N4 were used in this study. The genetic
background of TgMyof, TgMyof/Dysf prmd and Dysf prmd animals
were 87.5%, 90.6% and 93.75% of the C57BL/6 background.
Mice were injected into the left TA with different doses of two
different AAV-minidysferlin vectors (9.36107, 2.76108, 8.26109
or 1.661010 vg for the first preparation and 1.46108, 4.26108 or
1.36109 vg for the second preparation) in 30 ml. The construction
and production of the AAV vector was as previously described
[24]. Seven weeks after the injection, mice were sacrificed and
muscles were removed and quickly frozen in liquid nitrogen-
cooled isopentane.
Messenger RNA Quantification
Total RNA was extracted from muscles lysates by the Trizol
method (Invitrogen). Residual DNA was removed from the
samples using the Free DNA kit (Ambion). One mg of RNA was
reverse-transcribed using random hexamers and the Verso cDNA
kit (Abgene). Quantitative RT-PCR (RT-qPCR) analyses were
performed using the primer pairs and Taqman probe used for
myoferlin as follows. Myof.F: AGGCCCGTGGTGAAAGTT,
Myof.R: GGATTGTTCCCTCTCTTGATTCTC and probe
Myof.P: CATCTGTGGTCAGACGCACCGCA and for dysfer-
lin as follows. hDysf.F: GGCCTGGACCTCCCTTCA, hDysf.R:
TCAGGTCATCCAGGATCACATC and probe hDysf.P:
TCACCCCACGGAGAGCCAGAAGG. Total RNA from an
adult skeletal muscle served as quantification control (Stratagene
540029-41). The ubiquitous acidic ribosomal phosphoprotein (P0)
was used to normalize the data across samples. The global level of
overexpression was calculated relative to the quantification on
serial dilutions (16104 to 161010) of the myoferlin plasmid and
reported to one mg of RNA.
Western Blotting
Muscles were homogenized using FastPrep automated homog-
enizer (MP Biomedicals, Santa Ana, CA, USA) in lysis buffer
(20 mM pH 7.5 Tris, 150 mM NaCl, 2 mM EGTA, 0.1% 100X
Triton; 25 ml per mg of tissue) supplemented with Complete Mini
Protease Inhibitor Cocktail (Roche) and 2 mM E64 (Sigma).
Samples were mixed with loading buffer [NuPage LDS (Invitro-
gen), DTT 3 M (Sigma)], denatured for 10 minutes at 70uC and
briefly centrifuged. Proteins were separated by 3–10% poly-
acrylamide gradient NuPAGE gels (Invitrogen). After blotting,
efficacy of the transfer was verified by Ponceau Red staining (0.2%
Ponceau Red/1% acetic acid). Membranes were probed with
antibodies against myoferlin (SC51368 polyclonal antibody, Santa
Cruz, diluted 1/200), dysferlin (NCL-Hamlet, Novocastra, di-
lution 1/500), a-actin (A-2066, polyclonal antibody, Sigma,
diluted 1/400) or a-actinin (SC15335, polyclonal antibody, Santa
Cruz, diluted 1/200) at room temperature for 2–3 hours. Finally,
membranes were incubated with IRDyeH for detection by the
Odyssey infrared-scanner (LI-COR Biosciences, Lincoln, Ne-
braska, USA). Bound antibodies were detected at excitation
wavelengths of 600 or 800 nm. Relative protein levels were
quantified with the Odyssey 2.1 software (LI-COR Biosciences).
For subcellular fractionation, after homogenization using
FastPrep in lysis buffer supplemented with Complete Mini
Protease Inhibitor Cocktail (Roche), proteins were extracted with
the ProteoExtractH Subcellular Proteome Extraction Kit (S-PEK,
Calbiochem, Germany). Western blots were performed as de-
scribed above.
Histology and Immunohistochemistry
Cryosections (8 or 10 mm thickness) were prepared from frozen
muscles. Transverse sections were processed for Hematoxylin-
Phloxine-Saffron (HPS) staining. For HPS stained sections and
centro-nucleated fibers (CNF), digital images were captured using
a CCD camera (Sony) and processed using the Histolab software
(Microvision, Evry, France).
For immunodetection of myoferlin, sections were dried at room
temperature for 10 min. Sections were then incubated in blocking
solution (3% BSA in PBS) for 45 minutes. Then, they were
incubated over night at 4uC with the monoclonal antibodies
against myoferlin (SC-20, SantaCruz, diluted 1/50). After three
washes in PBS for 5 min each, sections were incubated with
secondary antibodies [donkey anti-goat antibody conjugated with
Alexa-594 dye (Invitrogen; dilution 1/1000)]. After three washes
Figure 4. Myoferlin overexpression and Minidysferlin do not prevent myofiber degeneration following eccentric contractions in
dysferlin-deficient muscle. A/Ten-week-old mice were subjected to LSI and their TA muscles were harvested 3 days after injury. EBD was injected
24 hours before tissue collection. Cryosections of TA muscles were studied under a fluorescent microscope to visualize Evans Blue dye. A high
number of EBD positive fibers were observed in Dysf prmd, TgMyof/Dysf prmd and rAAV2/1-Minidysferlin-injected Dysf prmd. The number of analyzed
samples is indicated in the graph. Scale Bar = 50 mm. B/The number of positive fibers were counted on the whole section and reported to the total
area of the section. Numbers of positive fibers are not statistically different in TgMyof/Dysf prmd and rAAV2/1-Minidysferlin-injected Dysf prmd
compared to Dysf prmd. C/HPS-stained muscle sections of the different conditions.
doi:10.1371/journal.pone.0038036.g004
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in PBS, the sections were mounted with Fluoromount G
(SouthernBiotech, Birmingham, USA) and examined under
a Leica confocal microscope at 594 nm.
For immunodetection of dysferlin, sections were boiled for
10 minutes in PBS for antigen retrieval, and then cooled for
10 minutes in PBS at room temperature. Sections were incubated
in Mouse-On-Mouse blocking reagent (Vector; MBK-2213).
Then, they were incubated over night at 4uC with the monoclonal
antibody dysferlin (Hamlet, diluted 1/20). After three washes PBS
for 5 min each, sections were incubated with biotinylated antibody
[F(ab)92 Goat anti-IgG1Mouse Biot (Southern Biotechnology;
diluted 1/200) for 60 min. After three washes in PBS, sections
were incubated with streptavidin antibody conjugated with Alexa-
488 dye (Invitrogen; S11223; diluted 1/1000) for 20 min. After
three washes in PBS, the sections were mounted with Fluoromount
G (SouthernBiotech, Birmingham, USA) and examined under
a Leica confocal microscope at 488 nm.
Fibers labeled with Evans Blue dye were revealed by
fluorescence excitation at 633 nm on a Leica confocal fluorescent
microscope. Images from the whole sections were taken using
a motorized stage at an original 40X magnification and ratio of the
area corresponding to the Evans Blue positive cells versus the
whole area of the section was measured using Image J in the red
channel.
Membrane Repair Assay
Membrane repair assays on isolated muscle were performed as
previously described [25].
Injury Model and Assessment of Contractile Function
Assessment of muscle function was performed by measuring the
contractile torques during a tetanus induced by a 300 ms pulse
trains using a rig previously described [41]. The LSI experiments
were performed as described [26]. Briefly, we used 15 lengthening
contractions to yield approximately 40% loss of contractile torque
in the ankle dorsiflexor group of muscles. For each lengthening
contraction, muscles were tetanically stimulated for 300 ms;
150 ms after onset of stimulation, the ankle was plantarflexed
from 90 to 175u at an angular velocity of 1200u/s. A 2-min rest
between successive lengthening contractions minimized the
possible effect of fatigue. Two days after the LSI, the mice were
injected intraperitoneally with Evans blue dye (1 mg/g of body
weight). The following day, mice were sacrificed and the TA
muscles were removed and quickly frozen in liquid nitrogen-
cooled isopentane.
Statistics Analysis
Data are presented as means 6 s.e.m. Individual means were
compared using the Mann-Whitney non-parametric test. Differ-
ences were considered to be statistically significant if p,0.05.
Supporting Information
Figure S1 Characterization of TgMyof. A/Assessment
of myoferlin levels in subcellular fractionations. The
distribution of myoferlin in TA muscles was examined by Western
analysis of subcellular fractions prepared using SPEK muscle
extract from WT and TgMyof mice. Equal volumes of each
fraction (nucleus, cytosol, membrane, cytoskeleton) were analyzed
and show a similar distribution between fractions despite the
overexpression (e.g. presence in the cytosol, nucleus and
membrane fraction). B/Contractile torque of TgMyof and
WT. The anterior compartment of the hindlimb of TgMyof and
WT animals was tetanically stimulated for 300 ms and the
contractile torques were measured. The differences were not
statistically significant.
(TIF)
Figure S2 AAV vector for minidysferlin. A/Upper
scheme: Scheme of the protein domain organization of the
dysferlin protein with its 7 C2 (from C2A to C2G), Fer, Dysf and
transmembrane domains. Middle scheme: Scheme of the
minidysferlin used in this study. Lower scheme: Scheme of
the rAAV construct for minidysferlin. B/Western Blot using
Hamlet antibody was performed with rAAV2/1-minidysferlin
injected and WT muscles and showed that the minidysferlin
protein was correctly expressed in injected muscles. An equal
amount of protein prepared from two minidysferlin-injected
Dysf prmd FDB muscles previously shown to be able to reseal was
added as control (left side of the blot). All parts of the image come
from the same gel. A-actin was used as a loading control.
(TIF)
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